Barrington keeps Buy rating for LeMaitre Vascular stock

LeMaitre Vascular (ISIN US5255582018) received a maintained Buy rating and a USD 95.00 price target from Barrington on October 1, 2026, according to Markets Insider. The company reported USD 70.38 million in revenue for the second quarter of 2026, up 9.60 percent from the same period a year earlier.

Barrington keeps USD 95.00 target

The analyst view gives LeMaitre a defined valuation reference after its latest quarterly report. Barrington's target is USD 15.95 above the USD 79.05 primary-exchange quote dated October 6, 2026, although the two figures belong to different markets and are not combined into a euro return calculation.

LeMaitre said its second-quarter 2026 sales increased 10.00 percent organically and announced a quarterly dividend of USD 0.25 per share in the August 4, 2026 release.

Quarterly growth meets a softer test

The earnings mix was constructive but less clean than the revenue growth alone suggests. LeMaitre reported diluted earnings per share of USD 0.74 for the second quarter of 2026, below the USD 0.81 consensus estimate, while revenue reached USD 70.38 million versus USD 71.47 million expected, MarketBeat reported on September 20, 2026.

Net profit for the quarter was USD 17.05 million, compared with USD 13.78 million in the year-earlier period, according to Markets Insider. For investors, the key tension is clear: operating growth remains visible, while the earnings miss leaves the USD 95.00 target dependent on execution in the next reporting cycle.

Prior close remains EUR 70.25

The prior close at Lang & Schwarz was EUR 70.25 on October 5, 2026. LeMaitre's market capitalization was USD 1.8 billion as of October 6, 2026, and its primary listing is Nasdaq under ticker LMAT.

The further course of trading is shown by the continuously updated real-time quote of LeMaitre Vascular stock.

More news and analyses on LeMaitre Vascular stock